GGrantIndex
← Leaderboards

Robert Henry Cichewicz

University Of Oklahoma

$10,878,573
Attributed
$16,696,781
Total exposure
14
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,696,781 · 14

By mechanism

R01$10,083,831 · 5
R21$2,939,143 · 7
U01$2,308,095 · 1
R33$1,365,712 · 1

Most similar at University Of Oklahoma

Same institution · by research overlap

Others in their field

Top investigators on “Source

Research focus

SourcePharmaceutical PreparationsLibrariesFungusDrug DiscoveryBaseLeadBiologicalNovel TherapeuticsResourcesStructureSamplingScaffoldInnovationNatural ProductsIn VitroScreeningLaboratoriesOklahomaEnvironmentExhibitsPublic Health RelevanceUniversitiesPrograms

Grant awards (44)

An LCMS-guided bioanalytical approach for rational natural product library design and optimization$259,912
R01 · FY2025 · GM
Novel Antimalarials from Fungi$754,049
R01 · FY2024 · AI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$265,497
R01 · FY2024 · GM
Novel Antimalarials from Fungi$755,877
R01 · FY2023 · AI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$205,280
R01 · FY2023 · GM
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$70,554
R01 · FY2023 · GM
Novel Antimalarials from Fungi$756,922
R01 · FY2022 · AI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$358,862
R01 · FY2022 · GM
Fungal natural products targeting antimicrobial resistant Mycoplasma genitalium$194,062
R21 · FY2022 · AI · contact PI
Novel Antimalarials from Fungi$758,201
R01 · FY2021 · AI
Fungal natural products targeting antimicrobial resistant Mycoplasma genitalium$246,625
R21 · FY2021 · AI · contact PI
Novel Antimalarials from Fungi$795,805
R01 · FY2020 · AI
Discovery of Novel Antimalarial Compounds from Fungi$224,611
R21 · FY2020 · AI
Early Stage Discovery of Natural Products Targeting Anaerobic Protozoal Pathogen$459,720
R33 · FY2019 · AI · contact PI
Discovery of Novel Antimalarial Compounds from Fungi$198,861
R21 · FY2019 · AI
Early Stage Discovery of Natural Products Targeting Anaerobic Protozoal Pathogen$459,720
R33 · FY2018 · AI · contact PI
New Leads for Triple Negative Breast Cancer from Diverse Natural Sources$459,144
U01 · FY2018 · CA
Exploiting Fungal Natural Products to Discover Novel Scaffolds That Inhibit Dormant and Drug-Resistant TB$186,189
R21 · FY2018 · AI
Sourcing Bioactive Secondary Metabolites from Great Lakes Fungi$555,984
R01 · FY2017 · GM · contact PI
New Leads for Triple Negative Breast Cancer from Diverse Natural Sources$459,144
U01 · FY2017 · CA
Early Stage Discovery of Natural Products Targeting Anaerobic Protozoal Pathogen$446,272
R33 · FY2017 · AI · contact PI
Exploiting Fungal Natural Products to Discover Novel Scaffolds That Inhibit Dormant and Drug-Resistant TB$235,314
R21 · FY2017 · AI
Sourcing Bioactive Secondary Metabolites from Great Lakes Fungi$555,984
R01 · FY2016 · GM · contact PI
New Leads for Triple Negative Breast Cancer from Diverse Natural Sources$459,144
U01 · FY2016 · CA
Early Stage Discovery of Natural Products Targeting Anaerobic Protozoal Pathogen$190,000
R21 · FY2016 · AI · contact PI
Procuring Native Natural Product Producers by In Situ Chimera Assembly$189,250
R21 · FY2016 · AI · contact PI
Sourcing Bioactive Secondary Metabolites from Great Lakes Fungi$554,157
R01 · FY2015 · GM · contact PI
New Leads for Triple Negative Breast Cancer from Diverse Natural Sources$459,144
U01 · FY2015 · CA
Procuring Native Natural Product Producers by In Situ Chimera Assembly$240,250
R21 · FY2015 · AI · contact PI
Early Stage Discovery of Natural Products Targeting Anaerobic Protozoal Pathogen$228,000
R21 · FY2015 · AI · contact PI
Sourcing Bioactive Secondary Metabolites from Great Lakes Fungi$589,594
R01 · FY2014 · GM · contact PI
New Leads for Triple Negative Breast Cancer from Diverse Natural Sources$471,519
U01 · FY2014 · CA
Chemically diverse antimicrobials from silent biosynthetic pathways$366,138
R01 · FY2014 · AI · contact PI
Chemically diverse antimicrobials from silent biosynthetic pathways$344,311
R01 · FY2013 · AI · contact PI
Antimicrobials from Mammalian Microbiomes$174,311
R21 · FY2013 · AI · contact PI
Accessing Natural Products from Silent Biosynthetic Pathways$367,485
R01 · FY2012 · GM · contact PI
Chemically diverse antimicrobials from silent biosynthetic pathways$366,432
R01 · FY2012 · AI · contact PI
Antimicrobials from Mammalian Microbiomes$217,000
R21 · FY2012 · AI · contact PI
Accessing Natural Products from Silent Biosynthetic Pathways$367,664
R01 · FY2011 · GM · contact PI
Chemically diverse antimicrobials from silent biosynthetic pathways$366,573
R01 · FY2011 · AI · contact PI
Chemically diverse antimicrobials from silent biosynthetic pathways$337,000
R01 · FY2010 · AI · contact PI
Accessing Natural Products from Silent Biosynthetic Pathways$331,550
R01 · FY2010 · GM · contact PI
Translating Natural Products into Therapeutic Leads for Huntington's Disease$188,325
R21 · FY2010 · NS · contact PI
Translating Natural Products into Therapeutic Leads for Huntington's Disease$226,345
R21 · FY2009 · NS · contact PI